?Vonoprazan Fumarate Intermediate 2 (CAS 881677-11-8) | High-Purity Building Block for Gastric Drug API Synthesis?
?Google Search Keywords?: Vonoprazan Fumarate Intermediate 2, CAS 881677-11-8, Vonoprazan Synthesis Material, P-CAB Intermediate, Gastric Drug API Precursor

?? ?Product Overview?
Vonoprazan Fumarate Intermediate 2 (CAS 881677-11-8) is a critical chemical component in the synthesis of ?Vonoprazan Fumarate?, a next-generation potassium-competitive acid blocker (P-CAB) used to treat gastric acid-related disorders like gastroesophageal reflux disease (GERD) and peptic ulcers. This intermediate ensures efficient and high-yield production of Vonoprazan Fumarate API, meeting stringent pharmaceutical quality requirements.
?Primary Function?: Enables scalable and impurity-controlled synthesis of Vonoprazan Fumarate API.
?Applications?: Gastrointestinal drug manufacturing, generic P-CAB development, clinical research.

? ?Key Advantages?
? ?Ultra-High Purity?

• Purity ≥99% (HPLC/LC-MS validated), minimizing unwanted byproducts and ensuring API quality.

?? ?Optimized Process Efficiency?

• Reduces synthesis time by 15-25% through streamlined reaction pathways, enhancing cost-effectiveness.

??? ?Enhanced Stability?

• Stable at controlled room temperature (15-25°C), suitable for global logistics and extended storage.

?? ?Regulatory Readiness?

• Manufactured under ?ICH Q7? and ?GMP? guidelines, compliant with USP/EP standards for intermediates.

?? ?Applications?

• ?API Production?: Key precursor in Vonoprazan Fumarate API synthesis for acid suppression therapies.

• ?Generic Drug Formulations?: Supports cost-effective alternatives to branded P-CAB medications.

• ?Digestive Health R&D?: Used to study novel P-CAB derivatives with improved pharmacokinetics.

• ?Clinical Trial Materials?: Critical for scaling up batches during pre-clinical and Phase I-III trials.

?? ?Quality Certifications?

1. Rigorously tested via ?HPLC, GC, NMR, and Mass Spectrometry? (USP/EP/ICH compliant).

2. Comprehensive Certificate of Analysis (CoA) with impurity profiles, spectral data, and chromatograms.

?? ?Market Trends?
The global gastric acid-related drug market is projected to grow at ?6.8% CAGR (2024-2030)?, driven by rising GERD prevalence and demand for potent P-CABs like Vonoprazan. Intermediate suppliers are crucial to meeting production needs, especially in Asia-Pacific markets where generic approvals are accelerating.

?? ?Why Choose Us??

• ?Custom Synthesis?: Tailored purity grades (98%-99.9%) and batch sizes (mg to kg scale).

• ?Fast Delivery?: Temperature-controlled shipping with real-time tracking and regulatory documentation.

• ?Technical Expertise?: End-to-end support for API synthesis, impurity control, and regulatory filings.